Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

BACKGROUND: Prostate cancer screening with prostate-specific antigen (PSA) has shown to reduce prostate cancer mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC) trial. Overdetection and overtreatment are substantial unfavourable side effects with consequent healthca...

Descripción completa

Detalles Bibliográficos
Autores principales: Heijnsdijk, E A M, der Kinderen, A, Wever, E M, Draisma, G, Roobol, M J, de Koning, H J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788248/
https://www.ncbi.nlm.nih.gov/pubmed/19904272
http://dx.doi.org/10.1038/sj.bjc.6605422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788248/
https://www.ncbi.nlm.nih.gov/pubmed/19904272
http://dx.doi.org/10.1038/sj.bjc.6605422

Ejemplares similares